Originally published as JCO Early Release 10.1200/JCO.2008.16.6496 on November 17 2008

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kim, H.-T. Articles by Ryu, J.-S. Search for Related Content PubMed PubMed Citation Articles by Kim, H.-T. Articles by Ryu, J.-S. Social Bookmarking                            What's this?

Effect of BRCA1 Haplotype on Survival of Non–Small-Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

Hong-Tae Kim, Jong-Eun Lee, Eun-Soon Shin, Yeon-Kyeong Yoo, Jae-Hwa Cho, Min-Hye Yun, Yeul-Hong Kim, Se-Kyu Kim, Hyun-Jung Kim, Tae-Won Jang, Seung-Min Kwak, Chul-Soo Kim, Jeong-Seon Ryu

From the Department of Biological Science, Sungkyunkwan University, Suwon; DNA Link Inc; College of Medicine, Korea University; College of Medicine, Yonsei University, Seoul; College of Medicine, Inha University, Incheon; and the College of Medicine, Kosin University, Pusan, South Korea

Corresponding author: Jeong Seon Ryu, MD, PhD, Pulmonary Division, Department of Internal Medicine, Inha University Hospital, 7-206, 3-Ga, Shinheung Dong, Jung Gu, Inchon, 400-103, Korea; e-mail: jsryu{at}inha.ac.kr

Purpose To determine whether germ-line variations in BRCA1 affect outcome in non–small-cell lung cancer (NSCLC) patients treated with platinum combination chemotherapy.

Patients and Methods We evaluated the associations of four tagging BRCA1 polymorphisms and their haplotypes with treatment outcome in 300 NSCLC patients at stages IIIA (16%), IIIB (31%), and IV (53%).

Results The median age was 63 years (range, 28 to 89 years). Histologically, 139 (46.3%) of the patients had squamous cell carcinomas and 137 (45.7%) had adenocarcinomas. Patient median survival time (MST) was 13.0 months. We observed no significant association between any of the tagging polymorphisms [S1613G, IVS13-1893 (A>C), IVS12-1207 (C>T), and IVS12+112 (C>A)] and overall survival. Of the five haplotypes evaluated (AACC, AACA, GCTC, GATC, and AATC), the survival of patients with two copies of the AACC (wild-type) haplotype was significantly shorter than that of patients with zero to one copies (MST, 8.47 v 14.57 months; log-rank P = .0066), even after adjustment for body weight loss, performance status, stage, second-line treatment, and radiation therapy (hazard ratio = 2.097; 95% CI, 1.339 to 3.284). The survival of patients with squamous cell carcinoma and two copies was significantly shorter than that of other patients with squamous cell carcinoma (MST, 6.8 v 15.3 months; log-rank P = 3.6 x 10^–5), whereas differences in survival between the two adenocarcinoma groups was not significant (log-rank P = .677).

Conclusion These findings suggest that the AACC haplotype of the BRCA1 gene is an important prognostic marker in NSCLC patients treated with platinum combination chemotherapy.

published online ahead of print at www.jco.org on November 17, 2008.

Supported by a research grant from Inha University.

H.-T.K. and J.-E.L. contributed equally to this article.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?